1. Aletaha, D. & Smolen, J.S. (2018) Diagnosis and management of rheumatoid arthritis: a review. JAMA, 320, 1360-1372.
2. Arnett, F.C., Edworthy, S.M., Bloch, D.A., McShane, D.J., Fries, J.F., Cooper, N.S., Healey, L.A., Kaplan, S.R., Liang, M.H., Luthra, H.S., et al. (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum., 31, 315-324.
3. Atsumi, T., Fujio, K., Yamaoka, K., Tomobe, M., Kuroyanagi, K. & Kameda, H. (2018) Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting. Mod. Rheumatol., 28, 780-788.
4. Burmester, G.R., Rubbert-Roth, A., Cantagrel, A., Hall, S., Leszczynski, P., Feldman, D., Rangaraj, M.J., Roane, G., Ludivico, C., Lu, P., Rowell, L., Bao, M. & Mysler, E.F. (2014) A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMACTA study). Ann. Rheum. Dis., 73, 69-74.
5. Dhillon, S. (2014) Intravenous tocilizumab: a review of its use in adults with rheumatoid arthritis. Biodrugs, 28, 75-106.